1 Title: Comparison of Peripheral Nerve Injury Outcomes Between COVID-19 Survivors and Non-COVID 2 Rehabilitation Inpatients: A Retrospective Study 3 **Authors:** Antonio Mondríguez-González MD*a; Brian M. Rothemich* BS b; Manasi Sheth PhDa1; Kevin N. 4 Swong^c; Colin K. Franz MD, PhD^{a, d, e, f} 5 6 a. Shirley Ryan Ability Lab: 355 E. Erie St, Chicago, IL 60611, USA 7 b. Virginia Commonwealth University School of Medicine: 1201 E Marshall St #4-100, Richmond, 8 VA 23298, USA 9 c. Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine: 420 10 E Superior St, Chicago, IL 60611, USA 11 d. Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of 12 Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA 13 e. Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of 14 Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA 15 f. Querrey Simpson Institute for Bioelectronics, Northwestern University Feinberg School of 16 Medicine, Chicago IL: 303 E. Superior St, Chicago, IL 60611, USA 17 *, denotes equal contribution by authors 18 19 Short Running Title: COVID-19 vs. Non-COVID PNI Outcomes 20 Corresponding Author: Colin K. Franz, Shirley Ryan AbilityLab, 26-North, 355 E. Erie Street, Chicago, 21 IL 60611, USA; cfranz@sralab.org 22 23

¹ Permanent address: 351 Evergreen Circle, Glendale Heights, IL 60139, USA

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Abstract Introduction: Peripheral nerve injury (PNI) is associated with severe Coronavirus disease 2019 (COVID-19) survivorship. The diagnosis of PNI is often made by a physiatrist during a detailed functional assessment during an inpatient rehabilitation stay. COVID-19 patients have elevated rates of medical comorbidities, including risk factors for acquired PNI, such as diabetes mellitus and obesity. It is not known if the functional prognosis from PNI in COVID-19 survivors differs substantially from PNI in other inpatient rehabilitation populations. Objective: To determine the prognosis of PNI associated with severe COVID-19 survivorship and compare it to PNI associated with other inpatient rehabilitation populations. **Design:** Retrospective chart review study. **Setting:** Single-center inpatient rehabilitation hospital in a large urban city. Patients: Adult patients admitted to an inpatient rehabilitation hospital with PNI(s). **Interventions:** Not applicable. Main Outcome Measures: The primary outcome was the change in manual muscle testing (MMT) over time. Secondary outcomes included the rate of peripheral nerve surgery and the number of distinct PNI sites per patient. Results: The analysis consisted of 60 subjects with PNI. We identified 30 subjects who had PNI associated with COVID-19 and were matched with 30 subjects with PNI not associated with COVID-19 who were diagnosed during their inpatient rehabilitation admission. The data collected included basic demographics, COVID-19 status immediately before inpatient rehabilitation admission, medical comorbidities, acute rehabilitation inpatient diagnosis, nerve injury location and mechanism of injury, muscles affected, and change in serial MMT, plus documentation of any surgical intervention. No significant difference was found between the improvement of MMT, surgery rate, or number of nerve injuries and COVID-19 status. Conclusion: PNIs associated with severe COVID-19 survivorship have similar recovery patterns as those of other etiologies. This data is reassuring that PNI associated with COVID-19 may be managed similarly to other types of PNI.

Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Coronavirus disease 2019 (COVID-19) has profoundly affected the world's health. As of August 2024, there have been 776 million confirmed disease cases. Furthermore, multiple studies suggest that survivorship issues from COVID-19 include an array of PNIs. Overall, although a variety of risk factors have been associated with acquired PNI from severe COVID-19, little is known about the clinical outcomes of these patients. To make matters worse, COVID-19 has been associated with multiple mononeuropathies in the same patient. For example, our group recently described a case series involving 66 PNIs found in 34 patients (average ~2 PNI/patient).2 This association of PNI with COVID-19 survivorship was noted early in the pandemic, including an observation that 12/83 post-COVID-19 patients consecutively admitted for inpatient rehabilitation had an acquired PNI,2 and just a few weeks later, a separate group described mononeuritis multiplex patterns in 11/69 COVID-19 patients consecutively admitted to an intensive care unit (ICU). Irrespective to the COVID-19 pandemic, the rates of PNI worldwide are ill-defined. Still, the best estimates come from developed countries with national healthcare registries with rates between 11 to 14 cases per 100,000 population per year.45 This is likely an underestimation of PNI incidence. For example, PNI can be an under-reported complication in the perioperative setting, overlooked or missed in cases of complex polytrauma, and in many countries like the United States that lack a national registry to study PNI; there are higher rates of PNI from gun violence. Outcomes from PNI are known to be highly variable regardless of whether patients undergo nerve repair surgery.8 Therefore, it is often challenging to prognosticate patient outcomes accurately. Prior studies have implicated age, site of injury, type of injury, and extent of vascular damage as the most important factors.89 Given the large numbers of people who survived severe COVID-19 and consequently were exposed to this risk for acquiring a PNI, the question of whether or not PNI outcomes are worse in survivors of severe COVID-19 is both important and unanswered. The purpose of this retrospective chart review study is to begin to define neurological recovery patterns and prognosis of PNIs associated with severe COVID-19 versus other non-COVID-19 associations. Since we have access to a relatively large and chronic series of patients who acquired PNI in association with admission for acute COVID-19, we performed a retrospective study to compare their recovery patterns and outcomes in follow-up against those of nonCOVID-19 associated PNI identified from inpatient rehabilitation patients diagnosed and treated in an overlapping time frame.

Materials and Methods

Study Subjects

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Study approval was granted by the Northwestern University Institutional Review Board. A total of 60 subjects with a diagnosis of PNI were included in this study. PNI in the context of this study is defined as mononeuropathy caused by traumatic etiologies such as gunshots, puncture wounds, and high-impact collisions and nontraumatic etiologies such as entrapment/compression, critical illness, severe COVID-19 survivorship, or medications leading to an impact on muscle strength and motor function. Subjects were selected from a registry of known PNI cases treated at the Shirley Ryan AbilityLab (an academic freestanding inpatient rehabilitation facility) in Chicago, IL (USA). Furthermore, subjects included in this study were equal to or greater than 18 years of age, and their PNI(s) must have been supported by electrodiagnostic studies. All subjects were patients admitted to inpatient rehabilitation who had their initial electrodiagnostic study and MMT conducted upon their rehabilitation hospital admission prior to their PNI being diagnosed. Subjects were placed into the post-COVID-19 PNI group if they acquired PNI(s) after admission to an acute care hospital for severe COVID-19 pneumonia. The post-COVID-19 PNI group was admitted to inpatient rehabilitation due to generalized weakness and deconditioning as a result of severe COVID-19 survivorship and its associated hospital complications. Severe COVID-19 survivorship was defined as recovery from an acute care hospitalization for COVID-19 requiring the use of assistive respiratory devices. Patients who were under the age of 18 or did not fit the rest of the inclusion criteria were excluded from data collection.

Study Outcomes

The primary outcome of this retrospective study is to compare the improvement of MMT from the initial diagnosis and after-treatment interventions. MMT was selected since it was well documented across patient charts and is a common clinical metric of peripheral nerve health. We were concerned that the improvement in MMT will be less in the post-COVID-19 group compared to other inpatient rehabilitation

patients (control group) due to the severity of their preceding illness, thus indicating a slower or reduced recovery process. The secondary outcome is to compare the surgery rate between these two groups. Due to the high rate of severe (axonotmesis) PNI associated with COVID-19,² we wondered if there may be a higher rate of nerve repair surgery within the post-COVID-19 group. The other secondary outcome is to compare the number of concomitant sites of PNI between the two groups. Since COVID-19 has been associated with mononeuritis multiplex patterns, we predicted that the post-COVID-19 group would be diagnosed with significantly more PNIs per patient.

Data Collection

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

Data was collected by retrospectively reviewing patients' electronic medical records with PNI from July 2018 to September 2023. A combination of electronic medical records from internal and external hospital systems was used to collect thorough data. We recorded several data points for each subject that consisted of age, race/ethnicity, whether or not the patient had COVID-19 before the PNI, comorbidities, acute rehabilitation inpatient status, mechanism of PNI, location of PNI, type of treatment intervention, electrodiagnostic studies at diagnosis, muscles affected by the PNI and their associated MMT scores at diagnosis and after treatment intervention. Each subject was screened for the following illnesses: diabetes mellitus, B12 deficiency, hypertension, hyperlipidemia, and obesity. The type of treatment was subdivided into no surgery, external neurolysis, direct nerve repair, nerve graft repair, and nerve transfer surgery. MMT grades were recorded with the standard 0-5 scale without modifiers (i.e., no 4+ or 4-). Only muscles tested during a documented physical exam and graded less than five were recorded at or within a month after initial electrodiagnostic studies. Follow-up MMT was done within 1 month of initial electrodiagnostic testing at either an outpatient or inpatient setting, depending on if the patient had been discharged from inpatient rehabilitation, although the latest available MMT was recorded for postintervention data points within a maximum of two years of the start of the intervention (physical therapy, surgery).

Data Preparation

When analyzing MMT data, the 60 subjects were further broken down into the specific nerve-injured and the associated muscle groups innervated by the nerve. Each nerve was then listed with its associated pre-intervention and post-intervention MMT grades. Each PNI was then categorized into one of three groups: no improvement, small improvement, and large improvement. No improvement was given if the difference in muscle grades was "0". Small improvement was given if the muscle grade improved by one MMT grade, except for a "4," progressing into a "5" to mitigate against the ceiling effect. Large improvement was given if the muscle grade improved to a "5" or improved by two or more MMT grades. Furthermore, if a PNI was not confirmed by a corresponding muscle group with a pre-intervention and post-intervention manual muscle test, it was removed from the data set (e.g., lateral femoral cutaneous nerve). In addition, if two or more muscle groups were associated with the PNI, only the muscle group with the highest level of improvement was included in the data set. If there was a tie in improvement level, then the most proximal muscle group with respect to the lesion site was included in the data set when paired with the PNI.

Statistical Analysis

Following data collection and preparation, a Student's t-test and several two-sided Fisher's exact tests were appropriately used to determine the presence of a statistically significant difference between ages, sex, race/ethnicities, comorbidities, and mechanism of injury for the post-COVID-19 PNI versus other non-COVID-19 PNI. A p-value of 0.05 was used when testing the statistical significance.

A Mann-Whitney U test was used to evaluate whether improvement in strength grading from MMT (no improvement, small improvement, large improvement) significantly differs by the COVID-19 status of PNI (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when testing the statistical significance.

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

A two-sided Fisher's exact test was used to determine if there was a significant association between treatment intervention and the COVID-19 status of PNI. A 2x2 contingency table was made to record the number of observations for treatment intervention (surgery versus no surgery) and the COVID-19 status of PNI (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when testing the statistical significance. A two-sided Fisher's exact test was used to determine if there was a significant association between the number of PNIs and post-COVID-19 status. A 2x2 contingency table was created to record the number of observations for each group. A p-value of 0.05 was used when testing the statistical significance. IRB and Data Storage This research study was approved by the Northwestern University IRB before data collection. Since this project is a retrospective chart review with no contact with subjects, no informed consent or waiver of consent was needed to gather and conduct research. All data documents with patient identifiers were encrypted and only available to the study investigators. All data was initially entered into a passwordprotected RedCap project database without patient identifiers. Before statistical analysis, all patient identifiers were removed from the final data collection document. Results Demographics, Comorbidities, and Mechanism of Nerve Injury A total of 60 subjects were analyzed in this study. Of these patients with PNIs, 30 subjects belong to the post-COVID-19 PNI group, while the remaining 30 subjects with other non-COVID-19 PNI belong to the control group. A summary of their characteristics can be seen in Table 1. Statistically significant differences were noted between the post-COVID-19 PNI group and the control group in the prevalence of diabetes (COVID n=19/30, non-COVID-19 3/30, p=0.0001), and hypertension (COVID n=22/30, non-COVID-19 8/30, p=0.0007). In addition, other statistically significant differences were found between the post-COVID-19 PNI group and the control group in the ages (COVID 55.9±12.2, non-COVID-19

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

43.2±16.2, p=0.001), and the Hispanic White racial/ethnicity group (COVID n=11/30, non-COVID-19 2/30, p=0.010). Lastly, the ratios of the mechanism of injury when comparing traumatic versus nontraumatic injuries proved to be statistically significant (COVID 0:30, non-COVID-19 19:11, p=0.0001). The ratios between sex, the remaining racial/ethnic groups, and obesity failed to reject the null hypothesis. MMT Comparison Results Improvements in MMT data are summarized in Figure 1A. A Mann-Whitney U test was used to evaluate whether improvement in strength grading from MMT (no improvement, small improvement, large improvement) significantly differs by the COVID-19 status of PNI (post-COVID-19 versus other non-COVID-19 associations). The null hypothesis stated no significant difference exists between the improvements in manual muscle tests and the COVID-19 status of PNI. The results indicated no significant difference between the improvement in manual muscle tests and the COVID-19 status of PNI (z = 1.5195, p = 0.1285).Surgery Comparison Results Surgical intervention data for each subject's PNI(s) is displayed in Table 1 and summarized in Figure 1B. We predicted that there would be a significantly higher surgery rate within the post-COVID-19 group, thus indicating that they require a more complicated recovery process due to the severity of the injuries. A Fisher's exact test was conducted to test the prediction that a significant association exists between treatment intervention and the COVID-19 status of PNI. The null hypothesis stated that no significant association exists between treatment intervention and the COVID-19 status of PNI. Using a 0.05 alpha, the null hypothesis failed to be rejected (two-tailed p = 0.1188). Therefore, there is no significant association between treatment intervention (no surgery versus surgery) and the COVID-19 status of PNI (post-COVID-19 versus other non-COVID-19 associations). Number of Nerve Injuries Comparison Results The number of nerve injuries for each subject is shown in Table 1 and summarized in Figure 1C. We predicted that there would be a significantly higher number of PNIs within the post-COVID-19 group. A

Fisher's exact test was conducted as outlined in the Materials and Methods section to test this prediction that there is a significant association between the number of PNIs and the COVID-19 status of the PNI. The null hypothesis stated that no significant association exists between the number of PNIs and the COVID-19 status of the PNI. Using a 0.05 alpha, the null hypothesis failed to be rejected (two-tailed p = 0.1188). Therefore, there is no significant association between the number of PNIs (one injury versus multiple injuries) and the COVID-19 status of the PNI (post-COVID-19 versus other non-COVID-19 associations).

Discussion

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Severe COVID-19 survivorship is associated with PNIs. Many of these COVID-19-associated PNIs tend to be severe, primarily associated with axonal injuries, and even with proper medical care, lead to significant disability in many patients. This prior data implied that COVID-19-associated PNIs may have less favorable outcomes than other types of PNIs. Upon initial evaluation, the COVID-19 PNI group had a statistically significant older sample and a higher presence of comorbidities such as diabetes and hypertension, as seen in Table 1. Older age, diabetes, and hypertension are risk factors for developing PNIs, while older age is a risk factor for poorer PNI prognosis. However, our retrospective analysis revealed no significant associations between improvement in MMT and whether or not the PNI was associated with COVID-19. Our findings reassure us that COVID-19-associated PNI patients do not have substantially different outcomes. In addition, there were no differences in the need for surgical intervention or the number of PNI sites/patients and COVID-19. Together, these results indicate COVID-19 COVID-19-associated PNI patients do not appear to have inherently worse outcomes than non-COVID-19 PNI patients. These results support using existing treatment guidelines for PNIs in this specific patient population. Severe COVID-19 patients appear to have an increased propensity for acquired PNI, and the potential reasons for this are likely multifactorial. Although the data is limited, in one neuropathological study of patients who died from COVID-19, muscle and nerve tissues exhibited signs of immune-mediated damage without direct infection by SARS-CoV-2, underscoring the impact of immune response rather

than viral invasion in nerve injuries associated with the disease." It appears that an interplay of

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

inflammatory and other immune-mediated factors results in a cytokine storm that directly damages nerve tissue and supporting vasculature. 12.13.14.15 combined with mechanical loading of nerves due to patient positioning while admitted in the ICU.16,17,18 Indeed, our group previously noted that PNI localizations seemed heavily biased to sites of known vulnerability to mechanical loading from direct compression or traction mechanisms.2 PNI management can vary depending on whether they are open or closed injuries. Open injuries from traumatic mechanisms such as laceration or transection generally benefit from early surgical repair (reanastomosis, grafting, etc.) when they are identified acutely. Meanwhile, closed injuries can be due to more diverse etiologies, from non-penetrating traumatic injury to chronic nerve entrapment injury, such as carpal tunnel syndrome. 9 Generally speaking, COVID-19-associated PNIs are closed injuries. Closed injuries require a thorough clinical assessment, usually including electrodiagnostic studies and serial reassessments, which can include advanced imaging with repeat electrodiagnostic studies and physical examination. If a closed PNI shows no signs of spontaneous axon regeneration, then patients may consider whether or not to undergo surgery, which may involve repair methods such as neurolysis, neuroma resection, and/or graft repair, as well as nerve transfer surgery.19 Physical and/or occupational therapy is an essential part of the pre-habilitation and post-surgical rehabilitation process. Interestingly, despite the non-COVID-19 PNI group of our study containing many more traumatic mechanisms of injury, the rate of surgery used to manage these two patient groups was not statistically different. The significance of this finding is uncertain, given the retrospective nature of our study. Since the recovery of COVID-19 patients with PNIs does not differ substantially from the control group, it appears that similar treatment algorithms may be applied to both groups. In addition to reinforcing current guidelines on PNI treatment management for severe COVID-19 survivors, this study should help rehabilitation physicians evaluate the prognosis of post-COVID-19 patients with PNIs. This study's findings suggest no difference in muscle strength recovery regardless of the mechanism of injury and association with severe COVID-19 survivorship. Ninety-two percent of patients with COVID-19-associated PNI gained back some level of muscle improvement, while 75% of other causes of PNI improved in motor deficits. A majority of patients experiencing motor improvement after PNI treatments is not unexpected and is in line

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

with multiple prior studies. For example, Kim et al. demonstrate that 73% of patients with thoracic outlet syndrome-associated motor deficits improved after appropriate treatment. Furthermore, another study with 107 patients with a variety of upper limb PNIs had a statistically significant improvement in all 107 patients' muscle strength after appropriate treatment. 20 Despite state-of-the-art treatments being made available to all PNI patients in this study, functional recoveries were near-universally incomplete.28 Partial functional recovery of PNIs remains a significant burden of disability of post-ICU survivors, including those that develop PNIs after severe COVID-19 survivorship.24 Although these PNIs associated with COVID-19 remain primarily axonal, no FDA-approved treatments are available to improve axon regeneration in this patient population. More clinical research should be conducted to find effective axonal regeneration treatments to reduce the functional disability of these patients. Evaluation of the study samples revealed possible health disparities due to the overrepresentation of a socially disadvantaged population. In the COVID-19-associated PNI sample, the distribution of race/ethnicity was 33.3%, 23.3%, and 36.7% for non-Hispanic white, non-Hispanic Black/African American, and Hispanic white, respectively. According to the 2018-2022 United States Census, Chicago's distribution of race/ethnicity was 32.7%, 28.8%, and 29.0% for non-Hispanic white, non-Hispanic Black/African American, and Hispanic white, respectively.²² The data demonstrates a large overrepresentation of patients who identify as Hispanic white in the severe COVID-19 PNI group. As seen in Table 1, a statistical analysis confirmed an overrepresentation of people who identify as Hispanic white in the COVID-19 PNI group. This overrepresentation could be due to a variety of factors. The Hispanic population in Chicago was the most likely ethnic group to work in essential and high-exposure jobs during the COVID-19 pandemic.23 In addition, there are social and economic factors within this ethnic group that reduce their access to healthcare, thus increasing their chances of developing complications due to severe COVID-19 survivorship.24 These risk factors and health disparities affiliated with COVID-19associated PNI can be further investigated in a subsequent study. It is important to recognize the scope of clinical impact this study has regarding the increased prevalence of PNIs in the study population. The rate of focal neuropathies associated with severe COVID-19 survivorship at inpatient rehabilitation facilities is approximately 10% compared to approximately 0.5% in

general rehab patients over the same time period.² PNIs subject patients to a substantial amount of long-term disability due to sensorimotor deficits and chronic neuropathic pain. Considering the high prevalence of PNIs associated with COVID-19 in the inpatient rehabilitation setting, physicians can implement the results from this study by confirming the effectiveness of their own clinical practices and existing treatment guidelines for addressing PNIs.

Limitations

The limitations need to be addressed before considering the full implications of this study. There is a relatively small sample of 60 subjects used in this study due to the limited number of qualifying subjects from a single healthcare facility. Both the smaller sample size and the location where the sample was collected reduce external validity; however, this study is still the largest single data set to report COVID-19 PNI long-term outcomes. In addition, since patient follow-ups occurred inconsistently and at varied time frames, the post-treatment MMT data was collected at different time intervals among the patients. Selection bias resulted from several patients or multiple muscle groups not being included in the MMT data analysis due to incomplete follow-up data. Incomplete follow-up data either resulted from patients not returning for follow-up visits entirely or follow-up visits only containing partial MMT data compared to their initial visit. These issues could potentially introduce bias by disproportionately increasing or decreasing the improvement in MMT for one or both groups. Lastly, due to the retrospective design of this study, outcome data for muscle strength improvement was limited to an outcome measure that is used routinely in clinical practice, such as MMT, rather than more objective and continuous data, such as torque production or electrophysical recordings.

Future Works

Several of these limitations can be addressed in future extensions of this study. For example, a larger sample size could increase the power of the results. The inclusion of multiple hospital systems, such as collaboration with other hospitals within our geographical region, could increase the external validity of the results. Furthermore, we hope to include phrenic neuropathy data in future iterations of this study by tracking improvements in diaphragm thickness ratios. Lastly, a multivariable regression analysis might

reveal complex associations not outlined in this paper, such as manual muscle improvement associated with race, gender, number of nerve injuries, treatment intervention, and COVID-19 status of nerve injury. Conclusion This data is impactful to the medical community as there is no literature to our knowledge that outlines the prognosis of this particular study population. This research fills a gap in the literature by providing a better understanding of the prognosis of post-COVID-19 PNIs. Because the results suggest there is no significant difference in prognosis between PNIs and their COVID-19 status, it can be inferred that physicians should not treat the two groups differently.

340 References 341 1. WHO Coronavirus (COVID-19) Dashboard. Accessed August 21, 2024. https://covid19.who.int 342 2. Franz CK, Murthy NK, Malik GR, et al. The distribution of acquired peripheral nerve injuries 343 associated with severe COVID-19 implicate a mechanism of entrapment neuropathy: a 344 multicenter case series and clinical feasibility study of a wearable, wireless pressure sensor. J 345 NeuroEngineering Rehabil. 2022;19(1):108. doi:10.1186/s12984-022-01089-1 346 3. Needham E, Newcombe V, Michell A, Thornton R, Grainger A, Anwar F, Warburton E, Menon D, 347 Trivedi M, Sawcer S. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-348 19. J Neurol. 2021 Aug;268(8):2685-2689. doi: 10.1007/s00415-020-10321-8. Epub 2020 Nov 26. 349 PMID: 33244712; PMCID: PMC7690651. 350 4. Murphy RNA, de Schoulepnikoff C, Chen JHC, et al. The incidence and management of 351 peripheral nerve injury in England (2005-2020). J Plast Reconstr Aesthet Surg. 2023;80:75-85. 352 doi:10.1016/j.bjps.2023.02.017 353 5. Asplund M, Nilsson M, Jacobsson A, von Holst H. Incidence of traumatic peripheral nerve injuries 354 and amputations in Sweden between 1998 and 2006. Neuroepidemiology. 2009;32(3):217-228. 355 doi:10.1159/000197900 356 6. Welch MB, Brummett CM, Welch TD, et al. Perioperative peripheral nerve injuries: a retrospective 357 study of 380,680 cases during a 10-year period at a single institution. Anesthesiology. 358 2009;111(3):490-497.doi:10.1097/ALN.0b013e3181af61cb 359 7. Stone L, Keenan MA. Peripheral nerve injuries in the adult with traumatic brain injury. Clin Orthop 360 Relat Res. 1988;(233):136-144. 361 8. Kim DH, Cho YJ, Tiel RL, Kline DG. Outcomes of surgery in 1019 brachial plexus lesions treated 362 at Louisiana State University Health Sciences Center. J Neurosurg. 2003;98(5):1005-1016. 363 doi:10.3171/jns.2003.98.5.1005 364 9. Hundepool CA, Ultee J, Nijhuis TH, Houpt P; Research Group 'ZERO'; Hovius SE. Prognostic 365 factors for outcome after median, ulnar, and combined median-ulnar nerve injuries: a prospective 366 study. J Plast Reconstr Aesthet Surg. 2015 Jan;68(1):1-8. doi: 10.1016/j.bjps.2014.09.043. Epub

367

2014 Sep 28. PMID: 25448370.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

10. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures. Brain. 2010;133(10):2838-2844. doi:10.1093/brain/awq270 11. Suh J. Mukerii SS, Collens SI, et al. Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19. Neurology. 2021;97(8):e849-e858. doi:10.1212/WNL.000000000012344 12. Zhang Y, Chen X, Jia L, Zhang Y. Potential mechanism of SARS-CoV-2-associated central and peripheral nervous system impairment. Acta Neurol Scand. 2022 Sep;146(3):225-236. doi: 10.1111/ane.13657. Epub 2022 Jun 14. PMID: 35699161; PMCID: PMC9349396. 13. Tutal Gursoy G, Yuksel H, Mulkem Simsek I, et al. Neurological Presentations in Patients with COVID-19 in Cytokine Storm. Can J Neurol Sci J Can Sci Neurol::1-7. doi:10.1017/cjn.2021.247 14. Li Z. Liu T. Yang N. et al. Neurological manifestations of patients with COVID-19; potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med. 2020;14(5):533-541. doi:10.1007/s11684-020-0786-5 15. De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review. Eur J Neurol. 2020;27(11):2361-2370. doi:10.1111/ene.14462 16. Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, Ko JH, Nussbaum RP, Dreyer SD, Jayabalan P, Walter JM, Franz CK. Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth. 2020 Dec;125(6):e478-e480. Doi: 10.1016/j.bja.2020.08.045. Epub 2020 Sep 4. PMID: 32948295; PMCID: PMC7473147 17. Miller C, O'Sullivan J, Jeffrey J, Power D. Brachial Plexus Neuropathies During the COVID-19 Pandemic: A Retrospective Case Series of 15 Patients in Critical Care. Phys Ther. 2021;101(1):pzaa191. doi:10.1093/ptj/pzaa191

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

18. Brugliera L, Filippi M, Del Carro U, et al. Nerve Compression Injuries After Prolonged Prone Position Ventilation in Patients With SARS-CoV-2: A Case Series. Arch Phys Med Rehabil. 2021;102(3):359-362. doi:10.1016/j.apmr.2020.10.131 19. Spinner RJ, Kline DG. Surgery for peripheral nerve and brachial plexus injuries or other nerve lesions. Muscle Nerve. 2000;23(5):680-695. doi:10.1002/(sici)1097-4598(200005)23:5<680::aidmus4>3.0.co;2-h 20. Milicin C, Sîrbu E. A comparative study of rehabilitation therapy in traumatic upper limb peripheral nerve injuries. NeuroRehabilitation. 2018;42(1):113-119. doi:10.3233/NRE-172220 21. Huebner EA, Strittmatter SM. Axon regeneration in the peripheral and central nervous systems. Results Probl Cell Differ. 2009;48:339-351. doi:10.1007/400 2009 19 22. U.S. Census Bureau QuickFacts: Chicago city, Illinois. Accessed December 26, 2023. https://www.census.gov/quickfacts/fact/table/chicagocityillinois/HSD410222 23. Schnake-Mahl AS, Lazo M, Dureja K, Ehtesham N, Bilal U. Racial and ethnic inequities in occupational exposure across and between US cities. SSM Popul Health. 2021;16:100959. doi:10.1016/j.ssmph.2021.100959 24. Pedraza L, Villela R, Kamatgi V, Cocuzzo K, Correa R, Lisigurski MZ. The Impact of COVID-19 in

the Latinx Community. HCA Healthc J Med. 3(3):97-104. doi:10.36518/2689-0216.1387

Subject Characteristics	COVID-19	Non-COVID	p-values (sig<0.05)	
Age	55.9 ± 12.2	43.2 ± 16.2	p=0.001	
Sex M:F	26:4 (n=30)	21:9 (n=30)	p=0.209	
Race/Ethnicities	Non-Hispanic White 33.3% (10/30)	Non-Hispanic White 60.0% (18/30)	Non-Hispanic White: p=0.069	
	Non-Hispanic Black/African American 23.3% (7/30)	Non-Hispanic Black/African American 16.7% (5/30)	Non-Hispanic Black/African American: p=0.748	
	Hispanic White 36.7% (11/30)	Hispanic White 6.7% (2/30)	Hispanic White: p=0.010	
	Unknown 6.7% (2/30)	Unknown 16.7% (5/30)	Unknown: p=0.437	
Comorbidities	Diabetes 63.3% (19/30)	Diabetes 10.0% (3/30)	Diabetes: p=0.0001	
	Obesity 43.3% (13/30)	Obesity 30.0% (9/30)	Obesity: p=0.422	
	Hypertension 73.3% (22/30)	Hypertension 26.7% (8/30)	Hypertension: p=0.0007	
Mechanism of Injury Traumatic:Nontraumatic	0:30 (n=30)	19:11 (n=30)	p=0.0001	

Table 1. Subject Characteristics. Significant p-values have been bolded.

	Cause of Neuropathy				
MMT Improvement	COVID-19 Associated (n=38)	Other Causes (n=36)			
No Improvement in Muscle Grade	8% n=3	25% n=9			
Small Improvement in Muscle Grade	1 6% n=6	17% n=6			
Large					

76%

n=29

(a)

421

422

423

424

425

426

427

Cause of Neuropathy

58%

n=21

	<u>Treatment</u> <u>Intervention</u>	COVID-19 Associated (n=30)	Other Causes (n=30)
(b)	No Surgery Treatment Intervention	43% n=13	67% n=20
	Surgery Treatment Intervention	57% n=17	33% n=10

Improvement

in Muscle Grade

Cause of Neuropathy COVID-19 Other **Associated** Causes Number of Nerve (n=30)(n=30)<u>Injuries</u> One Nerve 33% 57% Injury n=10 n=17 (c) **Multiple Nerve** 67% 43% **I**njuries n=20 n=13

Record ID	Age	Sex	Race and Ethnicity	Mechanism of Nerve Injury	COAID	Diabetes	Obesity	Hypertension	Surgical Intervention	Number of Nerve Injune
1	Over 65	Male	Non Hispanic White	Nontraumatic	Yes	No	Yes	No	Yes	1
2.	Over 65	Female	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	No	Yes	4
3	Over 65	Male	Non-Hispanie Black/African American	Nontratmatic	Yes	No	Yes	Yes	No	2.
4	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	4
5	33-64	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	1
6	55 64	Male	Non Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	No	1
7	55-64	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	Yes	No	1
8	55-64	Male	Hispanic White	Nontraumatic	Yes	No	Yea	Yes	Yes	2
9	Over 65	Female	Non Hispanic Black/African American	Nontraumatic	Yes	Yes	Yes	Yes	No	2
10	18-24	Female	Hispanic White	Nontraumatic	Yes	Yes	No	No.	No	ī
11	55 61	Male	Non Hispanic Black/African Amorican	Nontraumatio	Yes	Yes	No	You	No	2
12	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	Yes	2
13	35-44	I/emale	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	Yes	ī
14	55 64	Male	Non Hispanic Black/African American	Nontraumatic	Yes	Yes	No.	Yes	No	3
15	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	No.	No	5
16	25-34	Male	Unknown	Nontraumatic	Yes	Yes	Yes	Yes	No	3
17	55-64	Male	Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	б
18	33-64 Over 65	Male	Hispanic White	Nontraumatic	res Yes	Yes No	res Yes	Yes	res No	4
18	Over 65	Male Male		Nontraumatic Nontraumatic	Yes Yes	No No	Yes No	ves No	No No	1
			Non Hispanic White					Yes	Yes	3
20	Over 65	Male	Hispanic White	Nontraumatic	Yes	No	No			
21	45-54	Male	Hispanic White	Nontraumatic	Ycs	Yes	No	Yes	No	2
22	25 34	Male	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	No	1
23	Over 65	Female	Non-Hispanic Black/African American	Nontraumatic	No	No	Yes	Yes	No	2:
24	45-54	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	No	2
25	45-54	Male	Non-Hispanic White	Traumatic	No	No	Yes	Yes	No	1
26	18-24	Male	Hispanic White	Nontraumatic	No	No	No	No.	Yes	1
27	18 24	Female	Non Hispanic White	Traumatie	No	No	No	No	Yes	1
28	55-64	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	Yes	1
29	35-44	Male	Non-Hispanic White	Traumatic	No	Yes	No	No	Yes	4
30	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	4
31	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	7
32	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	No	Yes	Yes	1
33	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	Yes	Nυ	2
34	55-64	Male	Non-Hispanic White	Nontraumatic	No	No	No	No	Yes	4
35	55-64	Male	Non-Hispanic White	Nontraumatic	No	No	No	No	Yes	5
36	Over 65	Male	Non-Hispanie White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	3
37	25-34	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	i
38	35-44	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No	No	i
39	35-44	Male	Non-Hispanic White	Traumatic	No	No	No	No	No	3
40	18-24	Female	Non-Hispanic White	Traumatic	No	No	No	No.	No	i
41	18-24	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No.	No	3
42.	Over 65	Male	Non-Hispanic Mack/African American Non-Hispanic White	Traumatic	No	No	Yes	No.	No	1
47.	25.34	Male	Non Hispanic Black/African American	Traumatie	No	No	No	No	No	1
44	25 34 25-34	Male Male	Non Hispanic Black/Alrican American Hispanic White	Traumane	No No	No No	No No	No.	No No	1
										_
45	35-44	Male	Unknown	Traumatic	No No	No No	Yes	No No.	No No	1
46	18-24	Male	Unknown	Traumatic	Nο	No	No	No	No	2
47	55-64	Male	Non-Hispanic White	Nontraumatic	No	Ves	Yes	No.	No	
18	35 44	Female	Unknown	Traumatie	No	No	No	No	No	1
49	35-44	Female	Non-Hispanic White	Nontraumatic	Nσ	Nο	Yes	Yes	Yes	1
50	35.44	l/emale	Non Hispanic White	Nontraumatic	No	No	Yes	No.	Yes	1
51	55-64	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	1
52	Over 65	Male	Non-Hispanic Black/African American	Traumatic	No	Yes	No	No	No	1
53	18-24	Male	Non-Hispanie White	Traumatie	No	No	No	No	No	2
54	Over 65	Female	Non-Hispanic White	Nontraumatic	Nσ	Nο	No	Yes	No	2
55	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	1
56	15 54	Male	Unknown	Nontraumatic	Yes	Yes	No	No	No	2
57	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	No	No	Yes	No	1
38	55-64	Male	Non-Hispanic White	Traumatic	Nσ	No	No	No	No	3
59	55-64	Male	Unknown	Nontraumatic	Nσ	No	Yes	No	No	1
60	25-34	Male	Unknown	Traumatic	No	No	Yes	No	Yes	ā

Table 2. Demographics, Comorbidities, and Nerve Injuries.

Patient ID	Site of Nerve Injury	Grade Pre-Treatment Intervention	Grade Post-Treatment Intervention	No Improvement	Small Improvement	Large Improvement
1	Left Radial	2 (LWE)	5 (LWE)	No	No	Yes
2	Right Ulnar	3 (RFAB)	4 (RFAE)	No	Yes	Ne
2	Right Median	2 (RFF)	1 (RFF)	No	No	Yes
2	Right Radial	C (REE)	5 (REE)	No	No	Yes
7	Right Upper Trunk	4 (REF)	5 (REF)	No	No	Yes
9	Left C8 Root	4 (T.WF)	5 (T.WF)	No	Nn	Yes
10 11	Left Deep Peroneal	I (LADF)	4 (LADF)	No No	No No	Yes Yes
12	Right Common Peroneal Left Ulnar	0 (RAEV) 2 (LFAB)	3 (RAEV) 5 (LFAE)	No No	No No	Yes
12	Left Median	2 (LFRB) 2 (LFF)	5 (LFF)	No No	No	Yes
13	Right Upper Trunk	4 (REE)	5 (REE)	No	No	Yes
14	Right Spinal Accessory	1 (RSEL)	1 (RSEL)	No	No	Ves
14	Left Femoral	I (LHF)	2 (LHF)	No	Yes	No
14	Left Obturator	4 (LHAD)	5 (LHAD)	No	No	Yes
16	Left Deep Peroneal	I (LADF)	3 (LADF)	No	No	Yes
16	Right Deep Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
17	Right Sciatic	0 (RAPF)	3 (RAPF)	No	Nυ	Yes
17	Right Radial	0 (RWE)	3 (RWE)	No	Nυ	Yes
18	Right Median	4 (RFF)	4 (RFF)	Ycs	No	No
18	Right Upper Trunk	1 (REF)	1 (REF)	Yes	No	No
19	Right Common Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
20 20	Right Femoral	2 (RHF)	5 (RHF)	No No	No No	Yes Yes
20 21	Right Common Peroneal	1 (RADF)	4 (RADF)	No No	No Yes	Yes No
22	Left C5 Roct Left Sciatic	3 (LEF) 4 (LKF)	4 (LEF) 5 (LKF)	No No	No.	Yes
23	Left Common Peroneal	0 (LGTE)	1 (LGTE)	No	Yes	No.
24	Left Deep Peroneal	l (LADF)	1 (LADF)	Yes	No	No
21	Left Sciatic	2 (LAIN)	1 (LAIN)	No	No	Yes
25	Left Lumbocacral Plexus	2 (LADF)	4 (LADF)	No	No	Yes
26	Left Radial	0 (LWE)	5 (LWE)	No	No	Yes
27	Right Common Peroneal	0 (RADÉ)	4 (RADÉ)	No	No	Yes
28	Left Sciatic	0 (LADF)	3 (LADF)	No	No	Yes
29	Right Posterior Cord	0 (RWE)	5 (RWE)	No	No	Yes
29	Right Middle Trunk	C (REE)	5 (REE)	No	No	Yes
29	Right Upper Trunk	0 (REF)	5 (REF)	No	No	Yes
30	Left Median	4 (LTF)	5 (LTF)	No	Nυ	Yes
30	Right Ulnar	3 (RFAB)	5 (RFAB)	No	Nn	Ves
31	Left Radial	0 (LWE)	1 (LWE)	No	Yes	No
31	Left Middle Trunk	0 (LWE)	1 (LWE)	No	Yes	No
31 31	Right Middle Trunk	0 (REE) 2 (LEF)	4 (REE)	No No	No Yes	Yes No
31 31	Left Upper Trunk Right Upper Trunk	2 (LEF) 0 (REF)	3 (LEF) 4 (REF)	No No	res No	No Yes
32	Left Deep Peroneal	l (LADF)	4 (LADF)	No No	No No	Yes
33	Right Common Peroneal	I (RADF)	I (RADF)	Yts	Nυ	No.
33	Left Common Peroneal	l (LADF)	3 (LADF)	No	Nυ	Yes
34	Left Upper Trunk	0 (LWF)	3 (LWF)	No	No	Yes
31	Loft Middle Trunk	0 (LWE)	4 (LWE)	No	No	Yos
34	Left Lower Trunk	0 (LWF)	3 (LWF)	No	No	Yes
36	Right Upper Trunk	2 (REF)	5 (REF)	No	No	Yes
36	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
37	Left Suprascapular	2 (LSER)	5 (LSER)	No	No	Yes
38	Right Lateral Cord	2 (REF)	3 (REF)	No	Yes	No
39	Left C7 Root	0 (LFE)	2 (LFE)	No	No	Yes
39	Left C8 Root	2 (LFAB)	2 (LFAB)	Yes	No	No
39	Left Radial	0 (LFE)	2 (LFE)	No	No	Ves
10	Right Radial	0 (RWE)	1 (RWE)	No	Yes	No
42	Left Femoral	C (LHF)	3 (LHF)	No	No	Yes
44	Right Radial	4 (REE)	5 (REE)	No	No	Yes
45 46	Right Deep Peroneal	4 (RADF) 0 (LADF)	5 (RADF) 1 (LADF)	No No	No Yes	Yes No
40 47	Left Common Peroneal		4 (RFF)	No No	No.	Yes
4/	Right Median Right Ulnar	2 (RFF) 4 (RFAB)	1 (RFAB)	No Yes	No No	No.
49	Left Radial	0 (LWE)	5 (LWE)	No	No No	Yes
53	Right Sciatic	1 (RKF)	1 (RKF)	Yes	No	No
53	Left Common Peroneal	4 (LADF)	2 (LADF)	Yes	No	Ne
54	Left Sciatic	4 (LAPF)	4 (LAPF)	Yes	No	No
54	Left Femoral	1 (LHF)	0 (LHF)	Yes	No	No
55	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
58	Right Upper Trunk	0 (REF)	0 (REF)	Yes	No	No
58	Right Middle Trunk	C (REE)	0 (REE)	Y _{Co}	Nυ	Nυ
58	Right Lower Trunk	0 (RFAB)	1 (RFAD)	No	Yes	No
59	Right Femoral	2 (RIIF)	4 (RHF)	No	No	Yes
60	Right Upper Trunk	0 (REF)	1 (REF)	No	Yes	No
60	Right Middle Trunk	C (REE)	5 (REE)	No	No	Yes

Table 3. Manual Muscle Testing. Small Improvement (increase by one grade), Large Improvement (Increase to 5 or increase by two or more grades); (LSEL)/(RSEL)- left/right shoulder elevators, (LEF)/(REF)- left/right elbow flexors, (LEE)/(REE)- left/right elbow extensors, (LWF)/(RWF)- left/right wrist flexors, (LWE)/(RWE)- left/right wrist extensors, (LFF)/(RFF)- left/right finger flexors, (LFE)/(RFE)- left/right finger extensors, (LFAB)/(RFAB)- left/right finger abductors, (LTF)/(RTF)- left/right thumb flexors, (LHF)/(RHF)- left/right hip flexors, (LHAD)/(RHAD)- left/right hip adductors, (LKF)/(RKF)- left/right knee flexors, (LADF)/(RADF)- left/right ankle dorsiflexors, (LAPF)/(RAPF)- left/right ankle plantarflexors, (LAEV)/(RAEV)- left/right ankle evertors, (LGTE)/(RGTE)- left/right great toe extensors